1Shen H, Chen ZJ, Zilfou JT, et al. Ethyol WR-1065 administrated with transfer factor affect the reaction of cell to anticancer drugs [ J ]. J Phannacol Exp Ther., 2001,297 ( 3 ) :1067 - 1073.
2Bhatia S, Robison LI, Oberlin O, et al. Breast cancer and other second neoplasrnas after childhood Hodgkin' s disease[J]. N Engl J Med, 1996, 334:745 - 751.
3Volker Rudat, Jens Meyer, Felic Momm, et al. Prospective effect of amifostine on dental health after radiotherapy of the head and neck [ J ]. Int J Radiation Oncol, 2000, 48 (5) :1339 - 1343.
4Brizel Dm, Wasserman TH, Henke M, et al. Phase-Ⅲ randomized trial of amifostine as a radioprotector in head and neck cancer[J]. J CAin Oncol,2000,18(19):3339- 3345.
5Vikram B. Phase fll randomized trial of amitbstine as a radioprotector in head and neck[J] .J CAin Oncol ,2001 , 19(4) :1233 - 1234.
6Liu T, Liu Y, Ho S, et al. Use of radiation with or without WR-2721 in advanced rectal cancer[J]. Cancer, 1992,69:2820 - 2825.
7Bowslavizki Kh, Klutmann S, Brenner W, et al. Salivary gland protecting by amifostine in high-dose radioiodine treatment: results of a double-blind placebo-controlled study[J].J Clin Oncol, 1998, 16:3542- 3449.
8Buntzel J, Kutther K, Russel L, et al. Selective cytoprotein by amifostine in the treatment of head and neck cancer with simultaneous radiochemothempy [ J ]. Pro Am Soc Clin Oncol,1997, 16:393.
9Gridelli C, Guide C. Barletta E, et al. Thoracic radiotherapy and daffy vinorelbine as mdiosensitizer in locally ad-vanced non-small-cell lung cancer: a phase I study[J]. Lung Cancer,2000,29(2) : 131 - 137.
10Benett CL, Lane D, Stinson T, et al. Economic analysis of amifostine as adjunctive support for patients with advanced head and neck preliminary resultfrom a randomized phase H clinical trial from Germany[J]. Cancer Invest, 2001, 199(2) : 107 - 113.
